CIK 0001642380 · Non-accelerated filer<br>Smaller reporting company
Insight Molecular Diagnostics Inc.
Sign in to watch- Ticker
- IMDX
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 271041563
- Phone
- 949-409-7600
- Business address
- 2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE, TN, 37217
- Former names
- OncoCyte Corp, Oncocyte Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-12-16 | Paulsen Gisela Former President and COO | Returned to the company · Option to Purchase Common Stock | −171,875 | 203,125 | ||
| 2022-12-16 | Paulsen Gisela Former President and COO | Returned to the company · Option to Purchase Common Stock | −70,313 | 54,687 | ||
| 2022-12-16 | Paulsen Gisela Former President and COO | Returned to the company · Option to Purchase Common Stock | −125,000 | 0 | ||
| 2022-12-07 | ANDREWS RONALD ASBURY Former CEO | Grant or award · Option to Purchase Common Stock | +50,000 | 50,000 | ||
| 2022-12-01 | Ross Douglas T. Former CSO. | Returned to the company | −150,000 | 20,317 | ||
| 2022-12-01 | Paulsen Gisela Former President and COO | Returned to the company | −175,000 | 366,500 | ||
| 2022-12-01 | ANDREWS RONALD ASBURY Former CEO | Option exercise | +250,000 | 583,212 | ||
| 2022-12-01 | ANDREWS RONALD ASBURY Former CEO | Returned to the company · Option to Purchase Common Stock | −20,000 | 0 | ||
| 2022-12-01 | ANDREWS RONALD ASBURY Former CEO | Returned to the company · Option to Purchase Common Stock | −45,000 | 0 | ||
| 2022-12-01 | ANDREWS RONALD ASBURY Former CEO | Returned to the company · Option to Purchase Common Stock | −950,000 | 0 | ||
| 2022-12-01 | ANDREWS RONALD ASBURY Former CEO | Returned to the company · Option to Purchase Common Stock | −50,000 | 0 | ||
| 2022-12-01 | ANDREWS RONALD ASBURY Former CEO | Returned to the company · Option to Purchase Common Stock | −500,000 | 0 | ||
| 2022-12-01 | ANDREWS RONALD ASBURY Former CEO | Returned to the company · Option to Purchase Common Stock | −300,000 | 0 | ||
| 2022-12-01 | ANDREWS RONALD ASBURY Former CEO | Returned to the company · Option to Purchase Common Stock | −93,750 | 281,250 | ||
| 2022-12-01 | ANDREWS RONALD ASBURY Former CEO | Returned to the company · Restricted Stock Units | −35,000 | 0 | ||
| 2022-12-01 | ANDREWS RONALD ASBURY Former CEO | Returned to the company · Restricted Stock Units | −250,000 | 250,000 | ||
| 2022-12-01 | ANDREWS RONALD ASBURY Former CEO | Option exercise · Restricted Stock Units | −250,000 | 0 | ||
| 2022-08-17 | Last Andrew J. Director | Purchase | +20,000 | $0.87 | $17K | 70,170 |
| 2022-08-17 | Arno Andrew Director | Purchase | +7,500 | $0.90 | $7K | 15,000 |
| 2022-08-17 | Arno Andrew Director | Purchase | +7,500 | $0.90 | $7K | 15,000 |
Page 7 of 12 · 222 trades